Nasopharyngeal carcinoma (NPC) is a common malignant tumor with high invasive and metastatic potential. The hepatocyte growth factor (HGF)-Met signaling pathway has a critical role in mediating the invasive growth of many different types of cancer, including head and neck squamous cell carcinoma. HGF also stimulates NPC cell growth and invasion in the cell line model. In this study, we determined the inhibitory effect of Met, using a Met-targeting monoclonal antibody (SAIT301), on the invasive and growth potential of NPC cell lines. Met inhibition by SAIT301 resulted in highly significant inhibition of cell migration and invasion in both the HONE1 and HNE1 cell lines. In addition, we also found that co-treatment of SAIT301 and HGF decreased the anchorage-independent growth induced by HGF in HNE1 cell lines. After SAIT301 treatment, Met, together with its downstream signaling proteins, showed downregulation of p-Met and p-ERK, but not p-AKT, in both HONE1 and HNE1 cell lines. Interestingly, we found that HGF treatment of NPC cell lines induced early growth response protein (EGR-1) expression, which is involved in cell migration and invasion. In addition, co-treatment with SAIT301 and HGF inhibited the HGF-induced expression of EGR-1. Next, knockdown of EGR-1 using small-interfering RNA inhibited HGF-induced cell invasion in NPC cell lines, suggesting that the expression level of EGR-1 is important in HGF-induced cell invasion of NPC cells. Therefore, the results support that SAIT301 inhibited Met activation as well as the downstream EGR-1 expression and could have therapeutic potential in NPC. Taken together, we suggest that Met is an anticancer therapeutic target for NPC that warrants further investigation and clinical trials and SAIT301 may be a promising tool for NPC therapy.
Subject Category: Cancer Nasopharyngeal carcinoma (NPC) is malignant tumor that occurs in the epithelial lining of the nasopharynx, and has a high incidence in southern China, Southeast Asia, Alaska and North Africa. 1 The majority of patients with NPC are diagnosed as advanced disease with extremely common nodal metastasis. According to other papers previously published, at least 95% of NPC tumors regardless of histologic subtype have comorbid Epstein-Barr virus (EBV) infection 1 that is highly invasive and metastatic and differs from other head and neck cancers. 2 These tumorigenic and invasive potential of EBV are due to an unique set of latent genes: latent membrane proteins and EBV-determined nuclear antigens are the proteins predominantly expressed in NPC. 3 Especially, latent membrane proteins expression causes NPC cells to become migratory and invasive. 4 Unfortunately, the mechanism of NPC metastasis is not fully determined. While recent therapies for NPC include radiation and chemotherapy, 5 radioresistance remains a problem for successful clinical treatment.
Met, a proto-oncogene product receptor tyrosine kinase, is a specific receptor for hepatocyte growth factor (HGF), a cytokine of mesenchymal origin regulating various developmental processes by mediating epithelial-mesenchymal interaction. 6 The Met proto-oncogene, initially identified as a transforming gene from a chemically induced human osteogenic sarcoma cell line, 7 encodes a transmembrane glycoprotein with unique features composed of two disulfide-linked chains of a 50-kDa a subunit and a 145-kDa b subunit. 8 The a subunit is heavily glycosylated and extracellular. The b subunit consists of an extracellular portion involved in ligand binding, a membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The kinase domain contains critical phosphorylation sites regulating its kinase activity.
HGF binding to Met triggers receptor autophosphorylation and upregulation of Met kinase activity, which in turn stimulates a number of intracellular pathways mediating the biological effects of HGF, such as proliferation, motility, morphogenesis and angiogenesis. 11 In normal cells, Met activation is tightly controlled by a ligand-dependent transient event, whereas in tumor cells, Met is often constitutively activated. 12 Many different strategies have been exploited to inhibit aberrant Met signaling in various human cancer cells. These strategies target, directly or indirectly, the Met receptor and/or its ligand HGF. Direct methods include (1) HGF neutralizing antibodies or the use of the HGF antagonist NK4 or uncleavable proHGF to prevent ligand access to Met, 13, 14 (2) dominant-negative Met molecules, such as the recombinant sema domain of Met, decoy Met or anti-Met monoclonal antibody, 15 (3) small molecule ATP binding site inhibitors, such as K252a, PHA-665752 and SU11274, to prevent Met kinase activity, [16] [17] [18] (4) engineered SH2 domain polypeptides that interfere with access to the multidocking site 19 and (5) shRNA or ribozymes that reduce receptor or ligand expression. 20 Most of these approaches display selective inhibition of Met signaling. Indirect inhibition of Met signaling can be achieved by blocking Met downstream signaling pathways, such as the MAPK, PI3K or STAT3 pathways, which contribute to the malignant features of Met. 21 Recently, Horikawa et al. 22 reported that EBV latent membrane protein-1 induced upregulation of the Met protooncogene, which is correlated with cervical lymph-node metastasis of NPCs. Qian et al. 23 demonstrated that a high Met protein expression level correlates with poorer survival in late-stage NPC, and that the Met receptor in NPC is activated by its paracrine ligand HGF in the interstitial tissues rather than by an autocrine loop or an activating mutation.
Zhou et al. 24 identified HGF-induced invasion and migration, which is mediated by JNK through regulation of matrix metalloproteinase (MMP)-9, in response to PI3K/Akt signaling in NPC cells.
Early growth response protein (EGR-1) is a nuclear protein that contains three zinc finger motifs in the DNA-binding domain and is activated by growth factors (e.g., epidermal growth factor (EGF) or HGF), cytokines, hormones and environmental stresses. EGR-1 also has an important role in the regulation of tumor angiogenesis and tumor growth. Recently, Cheng et al. 25 have reported that EGR-1 was required for EGF-induced Slug expression involved in cell invasion in human ovarian cancer cells.
SAIT301, a novel Met antibody, was identified by Samsung Inc. (Yongin, Republic of Korea) and promotes LRR and immunoglobulin-like domain-containing protein 1 (LRIG1)-mediated Met degradation in a Cbl-independent manner. 26 In this study, we found that HGF-induced invasion and migration in NPC cell lines (HONE1 and HNE1) was inhibited by SAIT301, through downregulation of EGR-1 and Slug. Therefore, these results suggest that the Met monoclonal antibody, SAIT301, may be new anticancer therapeutic for controlling NPC progression and metastasis.
Results
Co-treatment with HGF and SAIT301 inhibits NPC cell migration and invasion. To examine the inhibitory effects of SAIT301 on the migration and invasion ability of HONE1 and HNE1 cells induced by HGF, we performed a wound-healing assay ( Figure 1a ) and a collagen-coatedtranswell-invasion assay ( Figure 1b) . As shown in Figure 1a , in the wound-healing assay, we scratched confluently growing HONE1 or HNE1 cells in 24-well plates and then pretreated with SAIT301 (1 mg/ml) for 1 h, followed by HGF treatment for 24 h. HGF induced narrowing of the scratch wound in both HONE1 and HNE1 cells; however, co-treatment with HGF and SAIT301 resulted in less cell migration than with HGF alone.
We further addressed the effect of SAIT301 on HONE1 and HNE1 cell invasion by using transwells, and found that co-treatment with HGF and SAIT301 significantly inhibited cell invasion compared with HGF alone (Figure 1b) , indicating that SAIT301 inhibited HGF-induced NPC cell migration and invasion.
SAIT301 inhibits anchorage-independent growth induced by HGF in HNE1 cells. The soft agar colony formation assay has been used to measure anchorageindependent cell growth, a hallmark of cell transformation. 27 To verify the inhibitory effect of SAIT301 on cell transformation in HNE1 cells, we performed the soft agar assay with or without HGF. As shown in Figure 2 , HGF-stimulated HNE1 cells grew well in soft agar, but co-treatment with SAIT301 and HGF in HNE1 significantly decreased colony size and number. From this result, it was concluded that SAIT301 could inhibit the ability of cancer cell transformation.
HGF-elicited signal transduction pathways were inhibited by SAIT301. We next attempted to identify the inhibitory effect of SAIT301 on HGF/Met signal transduction pathways. SAIT301 considerably reduced Met tyrosine phosphorylation on pY1003, pY1234/1235 and pY1349 sites activated by HGF. Furthermore, we also analyzed the downstream signaling of Met. ERK and AKT activation was determined by immunoblotting using phospho-specific antibodies. As shown in Figure 3a , SAIT301 displayed significant inhibitory activity on p-ERK, whereas the effect of SAIT301 was almost undetectable for p-AKT (Figure 3a ). To confirm that Met degradation was induced by SAIT301, Met was visualized by immunocytochemistry to determine its cellular location before and after SAIT301 treatment. When cells were stimulated with 1 mg/ml SAIT301 for 0.5 or 1 h, degradation of Met increased in the cytoplasm (Figure 3b ). The results suggested that Met degradation by SAIT301 inhibited the activation of downstream signaling of HGF-Met.
HGF induces the expression of EGR-1 and Slug. Lai et al. 28 have demonstrated that EGR-1 expression is required for HGF-induced KLF4 upregulation and cell scattering. To further elucidate the molecular mechanisms through which HGF stimulates EGR-1 expression and Slug, we performed western blot analysis using antibodies against EGR-1 and Slug. HGF upregulated the expression of EGR-1 at 1 h and the expression of Slug from 3 to 6 h ( Figure 4a ). Also to determine the inhibitory effect of SAIT301 on HGF-mediated EGR-1 and Slug expression, we pretreated with SAIT301 for 2 h before HGF treatment for 1 h in HONE1 and HNE1 cells, of which results interpreted that SAIT301 inhibited the HGF-induced expression of EGR-1 and Slug (Figures 4b and c) .
Knockdown of EGR-1 reduces cell invasion induced by HGF in HNE1 cells. To examine the effect of HGF-induced EGR-1 expression on cell invasion, we specifically knocked down EGR-1 in HNE1 cells. After transfection for 24 h, the transfected cells were seeded on collagen-coated transwells 
Discussion
Met is known to be overexpressed in oral, laryngeal and hypopharyngeal carcinomas in head and neck cancers. [29] [30] [31] Kim et al. 31 determined that the expression of HGF and Met was associated with lymph-node metastasis and the prognosis of patients with hypopharyngeal cancer. Lim et al. 32 investigated the expression of Met associated with cancer invasion and metastasis by studying the clinical/pathological features of small squamous cell carcinoma of the oral tongue (SCCOT) patients and identified that the overexpression of Met promotes invasion of tongue cancer cells.
NPC is a highly invasive and metastatic tumor in many parts of the world. 1 Binding of HGF to the extracellular region of Met triggers tyrosine autophosphorylation in the intracellular domain of Met and induces pleiotropic responses, such as proliferation, migration, invasion and angiogenesis in many types of cells.
11 Therefore, the abrogation of HGF-Met receptor coupling or Met receptor-mediated signaling events appears to be a promising strategy for prevention of tumor metastasis.
Recently, Lee et al. 33 identified a novel antibody, SAIT301, as a humanized anti-Met antibody that was originally developed from mouse immunization with a Met ectodomain and which promotes Met degradation in a Cbl-independent manner but exhibits minimal agonism. 26 They also demonstrated that SAIT301 promotes LRIG1-mediated Met degradation.
26 SAIT301-mediated Met degradation did not induce a significant agonism, further supporting the enhanced therapeutic potential of SAIT301. 26 The aim of this study was to determine the inhibitory role of SAIT301, a Met monoclonal antibody, in NPC cell lines for cancer therapy. The results of this study conclude that SAIT301 inhibited HGF-induced invasion and migration in both HONE1 and HNE1 cells (Figure 1 ). At this point, the cell death effect of SAIT301 on HGF-induced invasion and migration can be questioned. In order for us to evaluate and prove further about its cell death and proliferation in this regard, we used other head and neck cancer cells as well as NPC cell line (HONE1 and HNE1) and confirmed the occurrence of neither cell death nor short-term proliferation (MTT assay) by treating SAIT301 at different concentrations for 72 h (Supplementary Figure 1) . Therefore, we are suggesting that the cell death effect of SAIT301 on HGF-induced NPC invasion and migration is of little importance.
Looking at the overall results after multiple tests for the invasion by treating SAIT01, it was hard to see a significant invasion in NPC cancer cells, but rather SAIT single treatment caused a slight invasion. In fact, it showed a little activation of Met and Met downstream molecules whereas it exhibited much lower agonist activity than 5D5 (Genentech, Inc., South San Francisco, CA, USA) (e.g., phosphorylation of Met, AKT, Gab1 and other Met downstream cascade members, such as Shc, Stat1, ERK, Lck and Alk). 33 Although it has been difficult to produce bivalent anti-Met antibodies due to the frequent agonism occurring at various degrees from the bivalency, 34 SAIT301 has worked as an efficacious bivalent humanized monoclonal antibody with minimal agonism in spite of such challenging character and difficulties. 
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The prognosis of head and neck cancers depends on the metastasis that occurs in cancer cell migration and invasion. Therefore, NPC that is associated with the process is one of the key strategies to prevent cancer cells from migrating and invading. Although SAIT301 does not affect the cell viability or short-term proliferation (MTT assay) of NPC, it is found in the long-term proliferation of NPC on soft agar assay that SAIT301 slows down NPC proliferation and effectively reduces the migration and invasion, which can maximize the effectiveness of the treatment for NPC. Also, as shown in Figure 2 , HGF alone evidently increased the number and size of the cell colonies; however, cotreatment with HGF and SAIT301 decreased the number and size of colonies of HNE1 cells. Similar to our results, Li et al. 35 reported that knockdown of Met using siRNA inhibits the survival, proliferation and invasion of NPC cells. Zhou et al. 24 demonstrated that HGF, which is involved in the invasive phenotype and motility of NPC cells, is mediated by JNK through upregulation of MMP-9. However, we did not observe upregulation of MMP family genes induced by HGF in these cells.
Qian et al. 23 demonstrated that a high level of Met protein correlates with poorer survival in late-stage NPC, and that the Met receptor in NPC is activated by its paracrine ligand HGF from the interstitial tissues rather than by an autocrine loop or its activating mutation. When we examined the expression of Met using western blotting and HGF using ELISA in both HONE1 and HNE1 cell lines, Met was highly expressed, but basal p-Met (Figure 3a ) and HGF (data not shown) were rarely detected.
EGR-1 is rapidly activated by multiple extracellular agonists (such as growth factors and cytokines) and environmental stresses (such as hypoxia, fluid shear stresses and vascular injury). According to the report from Worden et al., 36 EGR-1 is a downstream transcription factor that differentially regulates HGF-induced proangiogenic factors such as PDGFA and VEGF expression in head and neck squamous cell carcinoma. Fahmy et al. 37 have shown that silencing EGR-1 expression with DNAzymes significantly inhibited the breast cancer growth and angiogenesis in vivo. However, it has not been yet reported the effect of EGR-1 on HGF-induced NPC invasion and migration.
As seen in Figure 5b , the invasion of EGR-1 siRNAtransfected cells was inhibited, compared with the control siRNA-transfected cells when treated with HGF (Figure 5b ). However, because the cells were incubated in serum-free condition, it is difficult to detect the cell invasion without HGF. Previously, we evaluated the significance of the serum HGF level in patients with HNSCC and found that the serum HGF level correlated significantly with the stage of the tumor progression. 38 Epithelial-mesenchymal transition (EMT) is an essential physiological process during the metastasis of cancer cells. Cancer cells can be induced to dissociate by being treated with growth factors (HGF, FGF, EGF and TGF families) through the change in expression of Snail, Slug or E-cadherin. Cheng et al. 39 have reported that EGF downregulates E-cadherin expression by upregulating Snail and Slug expression in human ovarian cancer cells. Savagner et al. 40 have reported the role and cell biological effects of the zinc finger protein Slug in FGF-1 or HGF-induced EMT such as desmosome dissociation, cell spreading, and the initiation of cell separation in rat bladder carcinoma cells. Also there is a research done by Huang et al. 41 suggesting that the knockdown of LEF1 inhibited the expression of Slug and markedly attenuated HGF-induced tumor migration and invasion. However, it has not been elucidated the role of Slug in HGF-induced NPC invasion and migration.
While Grotegut et al. 42 demonstrated that Snail has a critical role in HGF-mediated downregulation of E-cadherin and claudin-3 expression, thereby promoting cell scattering, migration and invasion, we detected the expression of Slug induced by HGF in NPC cells, but not Snail (Figure 4c) .
Lee et al. 26 showed that SAIT301 binds to an extracellular region of Met, generating an intracellular signal, which is different from the signal of other antibody such as 5D5 when bound to Met. They suggested that SAIT301 has minimal agonism due to its implication in Cbl-independent Met degradation. Our findings demonstrate that Met degradation by SAIT301 inhibited HGF-induced invasion and migration in NPC cell lines (HONE1 and HNE1) and conclude that the Met monoclonal antibody, SAIT301, can be a new anticancer therapeutic for controlling NPC progression and metastasis.
Materials and Methods
Cell culture and reagents. The human nasopharyngeal cell lines HONE1 and HNE1 were provided by Dr. Ronald Glaser 43 (The Ohio State University Wexner Medical Center, OH, USA). HONE1 cell lines were maintained in RPMI-1640 (Gibco/Invitrogen, Carlsbad, CA, USA) and HNE1 cell lines in Dulbecco's modified Eagle's medium (DMEM). The cell lines were maintained at 371C and 5% CO 2 in media supplemented with 10% fetal bovine serum (Gibco/Invitrogen). SAIT301 was provided by Samsung Advanced Institute of Technology (SAIT) in the Republic of Korea. 26 PBS was used as a solvent control. Recombinant human HGF was purchased from R&D System, Inc. (Minneapolis, MN, USA). Collagen Type I was purchased from Gibco/BRL, Inc. (Carlsbad, CA, USA).
Western blot analysis. Cell lysates were prepared and western blot analysis was performed as described previously. 44 Western blot analysis was performed using the following antibodies: p-Met (pY1234/1235, pY1349, pY1003), Met, p-ERK, ERK, p-AKT, AKT, EGR-1 and Slug (Cell Signaling Technology, Beverly, MA, USA). Relative intensity of individual protein bands was measured using image J, and the numbers represent the band densities normalized to a-Tubulin from same sample.
siRNA or plasmid transfection. Transfection with siRNA was performed as described previously.
45 HNE1 cells were transfected with EGR-1 siRNA (100 nM) using Lipofectamine 2000 (Gibco/Invitrogen). siRNA oligonucleotides were acquired from Genolution Pharmaceuticals (Seoul, Korea). The sense-strand sequences of siRNA duplexes were as follows: scrambled (as a control):
0 . After 24 h of siRNA transfection, the cells were changed to 1% low serum media for 24 h and pretreated with SAIT301 for 2 h, followed by treatment with HGF for 1 h.
Soft agar colony formation assay. HNE1 cells were diluted to 5 Â 10 3 cells/ml in 0.4% Noble agar solution in DMEM with 20% FBS. The cell suspension was added to each well of a 24-well plate on an underlayer of 0.8% Noble agar in DMEM with 20% FBS at 371C. Fresh DMEM containing 0.2% FBS with or without HGF (30 ng/ml) was added to the top of the soft agar and then cultured at 371C for 21 days. The culture medium was changed twice per week with or without HGF. The colonies were stained with a 0.05% crystal violet solution (dissolved in 20% methanol) and the stained colonies were counted using the Metamorph NX image software (Molecular Devices, Sunnyvale, CA, USA). Each experiment was performed in triplicate.
Wound-healing assay. Cells were plated on 24-well plates and grown to confluency, followed by serum deprivation for 24 h. Wounds were generated by using a sterile 200-ml pipette tip and washed with 1 Â PBS. Cells were then treated with SAIT301 and/or HGF for an additional 24 h. Three wells per experimental treatment were examined at Â 10 magnification by light microscopy. Each assays were done triple.
Invasion assay. Cell invasiveness was evaluated using collagen-coated transwell membrane inserts (BD Biosciences, Palo Alto, CA, USA). HONE1 or HNE1 cells were plated on the insert. Both inserts and lower wells were treated with vehicle control (PBS), SAIT301 and HGF. After 24 h, the cells in the insert were gently removed using a cotton swab. Cells on the reverse side of insert were fixed and stained with hematoxylin and eosin. The number of invading cells was counted in four representative fields per membrane by using light microscopy at Â 40 magnification. Each assays were done triple.
Immunocytochemistry. Cells grown on glass coverslips were fixed by 4% paraformaldehyde for 15 min. Non-specific binding was blocked with 1% bovine serum albumin (BSA). Coverslips were then incubated with anti-Met antibody (Cell Signaling) at 41C overnight. After three washes with PBS, the coverslips were incubated with the secondary FITC-conjugated goat anti-mouse IgG antibody diluted in PBS containing 1% BSA, washed repeatedly with PBS and mounted. The nucleus was stained with Hoechst 33258, and image processing was performed using a Zeiss LSM 710 confocal microscope (Zeiss, Jena, Germany) with a Â 40 water objective.
Statistical analysis. Statistical evaluation of the data was conducted using Student's t-test. Results were considered as statistically significant at Po0.05. 
